Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

By S. Garland, M. Hernández-Ávila, C. Wheeler, Gonzalo Pérez, D. Harper, S. Leodolter, G. W. Tang, D. Ferris, M. Steben, J. Bryan and 9 more. New England Journal of Medicine, 2007

2,030 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Microbiology

View Paper: https://www.semanticscholar.org/paper/273e54f7d5ecd079566273fecf0d3f42a53f469e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Who
2. Luisa Lina Villa
3. X. Castellsagué
4. L. Koutsky
5. S. Kjaer
6. M. Stanley

In Immunology

1. Who
2. D. Irvine
3. S. Mitragotri

Citations in the corpus

• Self-assembling protein nanoparticles in the design of vaccines (2015, neutral): “Structural proteins fromdifferentmicroorganisms have served as templates for the production of such nanoparticles and for the presentation of immunogenic epitopes: the protein pIII of the filamentous phage f1 [18], the Ty component from Saccharomyces cerevisiae [19], the surface and core antigens of”
• A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “Two phase III studies, FUTURE I [14] and FUTURE II [15], evaluated Gardasil® and two, PATRICIA [16] and the Costa Rica HPV Vaccine Trial (CVT) [17] evaluated Cervarix®.”
• Bio-inspired, bioengineered and biomimetic drug delivery carriers (2011, background): “The HPV-like particles resembled authentic HPV virions and induced protective immune responses against HP”
• Human papillomavirus vaccines: WHO position paper. (2009, background): “Among females naive to HPV-16 or HPV-18 for up to 1 month following the third dose of vaccine, protection against these combined end-points was 100% (95% confidence interval [CI], 94e100%) after a mean follow-up of 3 years [17].”
• Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. (2010, methodology): “The FUTURE II Study Group.”